Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02258074 · ClinicalTrials.gov registry record · Phase 2
The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE
A Phase 2 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
NCT02258074: Completed Phase 2 study, sponsored by The Cleveland Clinic.
NCT02258074 is a Phase 2 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 205 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02258074, a Phase 2 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
Study Summary
The COMBINE clinical trial is a pilot study evaluating the effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor 23 (FGF23) in patients with Chronic Kidney Disease (CKD) stages 3-4.
Primary Outcome
Change from baseline to 12 months in FGF23 level.
Interventions
- DRUG Nicotinamide
- DRUG Lanthanum Carbonate
- DRUG Placebo (for Nicotinamide)
- DRUG Placebo (for lanthanum carbonate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2015-03 |
| Est. Completion | 2019-09 |
| Phase | Phase 2 |
What the finished NCT02258074 record still lists
NCT02258074 is an interventional study that assigns participants to a tested intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% higher).
The record links to 0 conditions, and to 4 interventions - of which Nicotinamide is the first listed.
NCT02258074 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02258074 about?
NCT02258074 is a clinical study titled "The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE". The COMBINE clinical trial is a pilot study evaluating the effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor 23 (FGF23) in patients with Chronic Kidney Disease (CKD) stages 3-4.
What is the current status of trial NCT02258074?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2015-03. Estimated completion is 2019-09.
What interventions are being tested in trial NCT02258074?
The interventions under investigation include: Nicotinamide (DRUG), Lanthanum Carbonate (DRUG), Placebo (for Nicotinamide) (DRUG), Placebo (for lanthanum carbonate) (DRUG).
Who is sponsoring clinical trial NCT02258074?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02258074's enrollment target sits among peer trials
205 298th of 2000 higher than 1,702 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03457493 · 205 participants · Phase 1
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- NCT05134857 · 205 participants · Phase 2
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
- NCT05181891 · 205 participants · Phase 2
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
- NCT05283811 · 205 participants · NA
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia